Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of “Buy” by Brokerages

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has been assigned a consensus rating of “Buy” from the eight brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $30.00.

EYPT has been the topic of several analyst reports. Mizuho set a $28.00 price objective on Eyepoint Pharmaceuticals in a research note on Monday, October 20th. Cantor Fitzgerald upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, November 25th. Royal Bank Of Canada boosted their target price on Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, October 8th. Finally, TD Cowen raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Friday, December 19th.

Institutional Trading of Eyepoint Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EYPT. Invesco Ltd. increased its stake in Eyepoint Pharmaceuticals by 174.3% in the 1st quarter. Invesco Ltd. now owns 42,948 shares of the company’s stock worth $233,000 after buying an additional 27,291 shares during the period. American Century Companies Inc. bought a new position in Eyepoint Pharmaceuticals in the 1st quarter worth about $232,000. Corient Private Wealth LLC purchased a new position in shares of Eyepoint Pharmaceuticals during the second quarter worth approximately $1,200,000. Dynamic Technology Lab Private Ltd raised its stake in shares of Eyepoint Pharmaceuticals by 127.8% during the first quarter. Dynamic Technology Lab Private Ltd now owns 73,310 shares of the company’s stock valued at $397,000 after acquiring an additional 41,132 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Eyepoint Pharmaceuticals by 0.8% during the first quarter. Vanguard Group Inc. now owns 3,834,368 shares of the company’s stock valued at $20,782,000 after acquiring an additional 31,141 shares in the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

Eyepoint Pharmaceuticals Price Performance

Shares of EYPT opened at $18.29 on Friday. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -6.12 and a beta of 1.67. Eyepoint Pharmaceuticals has a 1 year low of $3.91 and a 1 year high of $19.11. The business’s 50 day simple moving average is $14.32 and its 200-day simple moving average is $12.39.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.08). The business had revenue of $0.97 million for the quarter, compared to the consensus estimate of $3.33 million. Eyepoint Pharmaceuticals had a negative net margin of 485.95% and a negative return on equity of 76.13%. On average, sell-side analysts expect that Eyepoint Pharmaceuticals will post -2.13 earnings per share for the current year.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.